drugset / Trial / NCT04450394
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
RandomizedParallel-groupOpen-labelTreatment
Summary
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2021-10-08
- Completion
- 2021-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Efsitora Alfa | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin degludec | Protein / enzyme biologic | 10 iu | Subcutaneous |